CAS No. |
83150-76-9 |
中文名称 |
(4R,7S,10S,13R,16S,19R)-13-((1H-吲哚-3-基)甲基)-19-((R)-2-氨基-3-苯基丙酰胺基)-10-(4-氨基丁基)-16-苄基-N-((2R,3R)-1,3-二羟基丁-2-基)-7-((R)-1-羟乙基)-6,9,12,15,18-五氧代-1,2-二硫杂-5,8,11,14,17-五氮杂环二十烷-4-甲酰胺 |
英文名称 |
(4R,7S,10S,13R,16S,19R)-13-((1H-indol-3-yl)methyl)-19-((R)-2-amino-3-phenylpropanamido)-10-(4-aminobutyl)-16-benzyl-N-((2R,3R)-1,3-dihydroxybutan-2-yl)-7-((R)-1-hydroxyethyl)-6,9,12,15,18-pentaoxo-1,2-dithia-5,8,11,14,17-pentaazacycloicosane-4-carboxamide |
别名 |
DARAMONOL;ctreotide;Ocetreotide, Acetate;L-Cysteinamide, D-phenylalanyl-L-cysteinyl-L-phenylalanyl-D-tryptophyl-L-lysyl-L-threonyl-N-(1R,2R)-2-hydroxy-1-(hydroxymethyl)propyl-, cyclic (2?7)-disulfide;OXTREOTIDE;[R-(R*,R*)]-D-Phenylalanyl-L-cysteinyl-L-phenylalanyl-D-tryptophyl-L-lysyl-L-threonyl-N-[2-hydroxy-1-(hydroxy-methyl)propyl]-cysteinamide cyclic(2->7)-disulfide;Octreotide acetate;L-cysteinamide, D-phenylalanyl-L-cysteinyl-L-phenylalanyl-D-tryptophyl-L-lysyl-L-threonyl-N-(2-hydroxy-1-(hydroxymethyl) propyl)-cyclic (2->7)-disulfide, (R-(R*,R*)) |
标准英文名 |
(4R,7S,10S,13R,16S,19R)-13-((1H-indol-3-yl)methyl)-19-((R)-2-amino-3-phenylpropanamido)-10-(4-aminobutyl)-16-benzyl-N-((2R,3R)-1,3-dihydroxybutan-2-yl)-7-((R)-1-hydroxyethyl)-6,9,12,15,18-pentaoxo-1,2-dithia-5,8,11,14,17-pentaazacycloicosane-4-carboxamide |
分子式 |
C49H66N10O10S2 |
分子量 |
1018.44
|
精确分子量 |
1018.44
|
SMILES |
O=C([C@@H](NC([C@H](CSSC[C@H](NC([C@](NC([C@@H](NC1=O)CCCCN)=O)([H])[C@H](O)C)=O)C(N[C@H](CO)[C@H](O)C)=O)NC([C@H](N)CC2=CC=CC=C2)=O)=O)CC3=CC=CC=C3)N[C@@H]1CC4=CNC5=CC=CC=C45 |
标准SMILES |
C[C@@H](O)[C@@H]1NC(=O)[C@H](CCCCN)NC(=O)[C@@H](CC2=CNC3=CC=CC=C23)NC(=O)[C@H](CC2C=CC=CC=2)NC(=O)[C@H](CSSC[C@H](NC1=O)C(=O)N[C@H](CO)[C@@H](C)O)NC(=O)[C@H](N)CC1C=CC=CC=1 |
用途 |
Octreotide acetate is used for:
1. Controlling symptoms in patients with acromegaly who are not adequately managed by surgery or radiotherapy, and reducing plasma levels of growth hormone (GH) and insulin-like growth factor-1 (IGF-1); it is also indicated for patients who are not candidates for or refuse surgery, or for those in the interim period before radiotherapy takes effect.
2. Alleviating symptoms associated with functional gastroenteropancreatic (GEP) endocrine tumors, such as carcinoid syndrome, VIPomas, and glucagonomas; however, it is not a curative anticancer agent.
3. Preoperative management of insulinomas to prevent hypoglycemia and maintain normoglycemia.
4. Adjunctive treatment of gastrinomas/Zollinger-Ellison syndrome (typically combined with proton pump inhibitors or H2-receptor antagonists).
5. Management of growth hormone-releasing factor-secreting tumors (with an approximate 50% efficacy rate).
6. Prevention of complications following pancreatic surgery.
7. Emergency treatment, hemostasis, and prevention of rebleeding in patients with esophageal variceal bleeding due to liver cirrhosis, used in combination with endoscopic sclerotherapy or other specific interventions. |
InChIKey |
DEQANNDTNATYII-OULOTJBUSA-N |